[1]
|
Barta, J.A., Powell, C.A. and Wisnivesky, J.P. (2019) Global Epidemiology of Lung Cancer. Annals of Global Health, 85, Article No. 8. https://doi.org/10.5334/aogh.2419
|
[2]
|
Cao, W., Chen, H.-D., Yu, Y.-W., Li, N. and Chen, W.-Q. (2021) Changing Profiles of Cancer Burden Worldwide and in China: A Secondary Analysis of the Global Cancer Statistics 2020. Chinese Medical Journal, 134, 783-791.
https://doi.org/10.1097/CM9.0000000000001474
|
[3]
|
Alexander, M., Kim, S.Y. and Cheng, H. (2020) Update 2020: Management of Non-Small Cell Lung Cancer. Lung, 198, 897-907. https://doi.org/10.1007/s00408-020-00407-5
|
[4]
|
Tocheva, A.S. and Mor, A. (2017) Checkpoint Inhibitors: Ap-plications for Autoimmunity. Current Allergy and Asthma Reports, 17, Article No. 72. https://doi.org/10.1007/s11882-017-0740-z
|
[5]
|
Mamdani, H., Matosevic, S., Khalid, A.B., Durm, G. and Jalal, S.I. (2022) Immunotherapy in Lung Cancer: Current Landscape and Future Directions. Frontiers in Immunology, 13, Article 823618.
https://doi.org/10.3389/fimmu.2022.823618
|
[6]
|
陈思, 赵泽锐, 龙浩. 新辅助免疫治疗及联合化疗在NSCLC中的研究进展[J]. 中国肺癌杂志, 2021, 24(4): 284-292.
|
[7]
|
Jiang, J., Wang, Y., Gao, Y., et al. (2022) Neoadjuvant Immunotherapy or Chemoimmunotherapy in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. Translational Lung Cancer Research, 11, 277-294.
https://doi.org/10.21037/tlcr-22-75
|
[8]
|
Forde, P.M., Chaft, J.E., Smith, K.N., et al. (2018) Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. New England Journal of Medicine, 378, 1976-1986. https://doi.org/10.1056/NEJMoa1716078
|
[9]
|
Lee, J., Chaft, J., Nicholas, A., et al. (2019) P2.04-88 Surgical Outcomes of a Multicenter Phase II Trial of Neoadjuvant Atezolizumab in Resectable Stages IB-IIIB NSCLC: Update on LCMC3 Clinical Trial. Journal of Thoracic Oncology, 14, S744. https://doi.org/10.1016/j.jtho.2019.08.1593
|
[10]
|
Tao, X., Li, N., Wu, N., et al. (2020) The Efficiency of 18F-FDG PET-CT for Predicting the Major Pathologic Response to the Neoadjuvant PD-1 Blockade in Resectable Non-Small Cell Lung Cancer. European Journal of Nuclear Medicine and Molecular Imaging, 47, 1209-1219. https://doi.org/10.1007/s00259-020-04711-3
|
[11]
|
Cascone, T., William Jr., W.N., Weissferdt, A., et al. (2021) Neoadjuvant Nivolumab or Nivolumab plus Ipilimumab in Operable Non-Small Cell Lung Cancer: The Phase 2 Ran-domized NEOSTAR Trial. Nature Medicine, 27, 504-514.
https://doi.org/10.1038/s41591-020-01224-2
|
[12]
|
Provencio, M., Nadal, E., Insa, A., et al. (2020) Neoadjuvant Chemotherapy and Nivolumab in Resectable Non-Small-Cell Lung Cancer (NADIM): An Open-Label, Multicentre, Sin-gle-Arm, Phase 2 Trial. The Lancet Oncology, 21, 1413-1422.
https://doi.org/10.1016/S1470-2045(20)30453-8
|
[13]
|
Forde, P.M., Spicer, J., Lu, S., et al. (2022) Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. New England Journal of Medicine, 386, 1973-1985. https://doi.org/10.1056/NEJMoa2202170
|
[14]
|
Kenmotsu, H., Sugawara, S., Watanabe, Y., et al. (2022) Adjuvant Atezolizumab in Japanese Patients with Resected Stage IB-IIIA Non-Small Cell Lung Cancer (IMpower010). Cancer Science, 113, 4327-4338.
https://doi.org/10.1111/cas.15564
|
[15]
|
Antonia, S.J., Villegas, A., Daniel, D., et al. (2017) Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. New England Journal of Medicine, 377, 1919-1929. https://doi.org/10.1056/NEJMoa1709937
|
[16]
|
Antonia, S.J., Villegas, A., Daniel D., et al. (2018) Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. New England Journal of Medicine, 379, 2342-2350. https://doi.org/10.1056/NEJMoa1809697
|
[17]
|
Spigel, D.R., Faivre-Finn, C., Gray, J.E., et al. (2022) Five-Year Survival Outcomes from the PACIFIC Trial: Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 40, 1301-1311.
https://doi.org/10.1200/JCO.21.01308
|
[18]
|
Zhou, Q., Chen, M., Wu, G., et al. (2020) GEMSTONE-301: A Phase III Clinical Trial of CS1001 as Consolidation Therapy in Patients with Locally Advanced/Unresectable (Stage III) Non-Small Cell Lung Cancer (NSCLC) Who Did Not Have Disease Progression after Prior Concurrent/Sequential Chemoradiotherapy. Translational Lung Cancer Research, 9, 2008-2015. https://doi.org/10.21037/tlcr-20-608
|
[19]
|
Jabbour, S.K., Lee, K.H., Frost, N., et al. (2021) Pembrolizumab plus Concurrent Chemoradiation Therapy in Patients with Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer: The Phase 2 KEYNOTE-799 Nonrandomized Trial. JAMA Oncology, 7, 1351-1359. https://doi.org/10.1001/jamaoncol.2021.2301
|
[20]
|
Augustyn, A., Adams, D.L., He, J., et al. (2021) Giant Circulat-ing Cancer-Associated Macrophage-Like Cells Are Associated with Disease Recurrence and Survival in Non-Small-Cell Lung Cancer Treated with Chemoradiation and Atezolizumab. Clinical Lung Cancer, 22, e451-e465. https://doi.org/10.1016/j.cllc.2020.06.016
|
[21]
|
虞思来, 倪建佼, 朱正飞. 免疫治疗时代不可手术局部晚期非小细胞肺癌的治疗: 现状与展望[J]. 中国癌症杂志, 2022, 32(6): 487-498. https://doi.org/10.19401/j.cnki.1007-3639.2022.06.003
|
[22]
|
Jabbour, S.K., Cho, B.C., Bria, E., et al. (2022) Ra-tionale and Design of the Phase III KEYLYNK-012 Study of Pembrolizumab and Concurrent Chemoradiotherapy Fol-lowed by Pembrolizumab with or without Olaparib for Stage III Non-Small-Cell Lung Cancer. Clinical Lung Cancer, 23, e342-e346. https://doi.org/10.1016/j.cllc.2022.04.003
|
[23]
|
De Ruysscher, D., Ramalingam, S., Urbanic, J., et al. (2022) CheckMate 73L: A Phase 3 Study Comparing Nivolumab plus Concurrent Chemoradiotherapy Followed by Nivolumab with or without Ipilimumab Versus Concurrent Chemoradiotherapy Followed by Durvalumab for Previously Untreated, Locally Advanced Stage III Non-Small-Cell Lung Cancer. Clinical Lung Cancer, 23, e264-e268. https://doi.org/10.1016/j.cllc.2021.07.005
|
[24]
|
高鸣, 周清, 吴一龙. 免疫时代下不可手术Ⅲ期非小细胞肺癌治疗变革[J]. 循证医学, 2022, 22(1): 23-29.
https://doi.org/10.12019/j.issn.1671-5144.2022.01.001
|
[25]
|
Reck, M., Rodriguez-Abreu, D., Robinson, A.G., et al. (2021) Five-Year Outcomes with Pembrolizumab versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer with PD-L1 Tumor Proportion Score ≥ 50%. Journal of Clinical Oncology, 39, 2339-2349. https://doi.org/10.1200/JCO.21.00174
|
[26]
|
Reck, M., Rodriguez-Abreu, D., Robinson, A.G., et al. (2019) Updated Analysis of KEYNOTE-024: Pembrolizumab versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer with PD-L1 Tumor Proportion Score of 50% or Greater. Journal of Clinical Oncology, 37, 537-546. https://doi.org/10.1200/JCO.18.00149
|
[27]
|
Mok, T.S.K., Wu, Y.-L., Kudaba, I., et al. (2019) Pembrolizumab ver-sus Chemotherapy for Previously Untreated, PD-L1-Expressing, Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (KEYNOTE-042): A Randomised, Open-Label, Controlled, Phase 3 Trial. Lancet, 393, 1819-1830. https://doi.org/10.1016/S0140-6736(18)32409-7
|
[28]
|
Herbst, R.S., Giaccone, G., De Marinis, F., et al. (2020) Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC. New England Journal of Medicine, 383, 1328-1339. https://doi.org/10.1056/NEJMoa1917346
|
[29]
|
Liu, G., Kang, S., Wang, X. and Shang, F. (2021) Cost-Effectiveness Analysis of Atezolizumab versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer with Different PD-L1 Expression Status. Frontiers in Oncology, 11, Article 669195. https://doi.org/10.3389/fonc.2021.669195
|
[30]
|
Gogishvili, M., Melkadze, T., Makharadze, T., et al. (2022) Cemi-plimab plus Chemotherapy versus Chemotherapy Alone in Non-Small Cell Lung Cancer: A Randomized, Controlled, Double-Blind Phase 3 Trial. Nature Medicine, 28, 2374-2380. https://doi.org/10.1038/s41591-022-01977-y
|
[31]
|
Xu, C.-R., Chen, Q., Zhou, C., et al. (2023) Effectiveness and Safety of Camrelizumab in Inoperable or Advanced Non-Small Cell Lung Cancer Patients: A Multicenter Real-World Retrospective Observational Study (CTONG2004-ADV). Translational Lung Cancer Research, 12, 127-140. https://doi.org/10.21037/tlcr-22-852
|
[32]
|
Gandhi, L., Rodriguez-Abreu, D., Gadgeel, S., et al. (2018) Pembroli-zumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. New England Journal of Medicine, 378, 2078-2092.
https://doi.org/10.1056/NEJMoa1801005
|
[33]
|
Zhou, C., Chen, G., Huang, Y., et al. (2021) Camrelizumab plus Carboplatin and Pemetrexed versus Chemotherapy Alone in Chemotherapy-Naive Patients with Advanced Non-Squamous Non-Small-Cell Lung Cancer (CameL): A Randomised, Open-Label, Multicentre, Phase 3 Trial. The Lancet Respiratory Medicine, 9, 305-314.
https://doi.org/10.1016/S2213-2600(20)30365-9
|
[34]
|
Yang, Y., Wang, Z., Fang, J., et al. (2020) Efficacy and Safety of Sintilimab plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: A Randomized, Double-Blind, Phase 3 Study (Oncology Program by InnovENT Anti-PD-1-11). Journal of Thoracic Oncology, 15, 1636-1646.
https://doi.org/10.1016/j.jtho.2020.07.014
|
[35]
|
Lu, S., Wang, J., Yu, Y., et al. (2021) Tislelizumab plus Chemo-therapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial. Journal of Thoracic Oncology, 16, 1512-1522. https://doi.org/10.1016/j.jtho.2021.05.005
|
[36]
|
Li, W. and Wan, L. (2022) Cost-Effectiveness Analysis of Sugemalimab vs. Placebo, in Combination with Chemotherapy, for Treatment of First-Line Metastatic NSCLC in China. Frontiers in Public Health, 10, Article 1015702.
https://doi.org/10.3389/fpubh.2022.1015702
|
[37]
|
Ren, S., Chen, J., Xu, X., et al. (2022) Camrelizumab plus Car-boplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial. Journal of Thoracic Oncology, 17, 544-557.
https://doi.org/10.1016/j.jtho.2021.11.018
|
[38]
|
West, H., Mccleod, M., Hussein, M., et al. (2019) Atezolizumab in Combination with Carboplatin plus Nab-Paclitaxel Chemotherapy Compared with Chemotherapy Alone as First-Line Treatment for Metastatic Non-Squamous Non- Small-Cell Lung Cancer (Impower130): A Multicentre, Randomised, Open-Label, Phase 3 Trial. The Lancet Oncology, 20, 924-937. https://doi.org/10.1016/S1470-2045(19)30167-6
|
[39]
|
Paz-Ares, L., Luft, A., Vicente, D., et al. (2018) Pembroli-zumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. New England Journal of Medicine, 379, 2040-2051. https://doi.org/10.1056/NEJMoa1810865
|
[40]
|
Wang, J., Lu, S., Yu, X., et al. (2021) Tislelizumab plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncology, 7, 709-717. https://doi.org/10.1001/jamaoncol.2021.0366
|
[41]
|
Zhou, C., Wu, L., Fan, Y., et al. (2021) Sintilimab plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results from a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12). Journal of Thoracic Oncology, 16, 1501-1511. https://doi.org/10.1016/j.jtho.2021.04.011
|
[42]
|
Hellmann, M.D., Paz-Ares, L., Bernabe Caro, R., et al. (2019) Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. New England Journal of Medicine, 381, 2020-2031. https://doi.org/10.1056/NEJMoa1910231
|
[43]
|
Brahmer, J.R., Lee, J.-S., Ciuleanu, T.-E., et al. (2023) Five-Year Survival Outcomes with Nivolumab plus Ipilimumab versus Chemotherapy as First-Line Treatment for Meta-static Non-Small-Cell Lung Cancer in CheckMate 227. Journal of Clinical Oncology, 41, 1200-1212. https://doi.org/10.1200/JCO.22.01503
|
[44]
|
Paz-Ares, L., Ciuleanu, T-E., Cobo, M., et al. (2021) First-Line Nivolumab plus Ipilimumab Combined with Two Cycles of Chemotherapy in Patients with Non-Small-Cell Lung Cancer (CheckMate 9LA): An International, Randomised, Open-Label, Phase 3 Trial. The Lancet Oncology, 22, 198-211. https://doi.org/10.1016/S1470-2045(20)30641-0
|
[45]
|
Liang, H. and Wang, M. (2019) Prospect of Immunotherapy Combined with Anti-Angiogenic Agents in Patients with Advanced Non-Small Cell Lung Cancer. Cancer Management and Research, 11, 7707-7719.
https://doi.org/10.2147/CMAR.S212238
|
[46]
|
Huang, Y., Kim, B.Y.S., Chan, C.K., et al. (2018) Improving Im-mune-Vascular Crosstalk for Cancer Immunotherapy. Nature Reviews Immunology, 18, 195-203. https://doi.org/10.1038/nri.2017.145
|
[47]
|
Socinski, M.A., Jotte, R.M., Cappuzzo, F., et al. (2018) Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. New England Journal of Medicine, 378, 2288-2301. https://doi.org/10.1056/NEJMoa1716948
|
[48]
|
Chen, S., Wu, Z., Shi, F., et al. (2022) Lenvatinib plus TACE with or without Pembrolizumab for the Treatment of Initially Unresectable Hepatocellular Carcinoma Harbouring Pd-L1 Ex-pression: A Retrospective Study. Journal of Cancer Research and Clinical Oncology, 148, 2115-2125. https://doi.org/10.1007/s00432-021-03767-4
|
[49]
|
董琳, 刘欣, 鲁海玲. 晚期非小细胞肺癌抗血管生成治疗联合免疫检查点抑制剂的研究进展[J]. 实用肿瘤学杂志, 2022, 36(4): 351-355. https://doi.org/10.11904/j.issn.1002-3070.2022.04.011
|
[50]
|
Ren, S., He, J., Fang, Y., et al. (2022) Camrelizumab plus Apatinib in Treatment-Naive Patients with Advanced Nonsquamous NSCLC: A Multicenter, Open-Label, Sin-gle-Arm, Phase 2 Trial. Clinical and Research Reports, 3, Article ID: 100312. https://doi.org/10.1016/j.jtocrr.2022.100312
|
[51]
|
崔广华, 杨宇. 安罗替尼在晚期恶性肿瘤治疗中的研究进展[J]. 现代肿瘤医学, 2022, 30(16): 3032-3036.
https://doi.org/10.3969/j.issn.1672-4992.2022.16.034
|
[52]
|
Maruhashi, T., Sugiura, D., Okazaki, I.M. and Okazaki, T. (2020) LAG-3: From Molecular Functions to Clinical Applications. Journal for ImmunoTherapy of Cancer, 8, e001014. https://doi.org/10.1136/jitc-2020-001014
|
[53]
|
Zhao, B.-W., Zhang, F.-Y., Wang, Y., et al. (2022) LAG3-PD1 or CTLA4-PD1 Inhibition in Advanced Melanoma: Indirect Cross Comparisons of the CheckMate-067 and RELATIVITY-047 Trials. Cancers, 14, Article No. 4975.
https://doi.org/10.3390/cancers14204975
|
[54]
|
苏春霞, 周彩存. 晚期非小细胞肺癌免疫治疗现状及未来方向[J]. 中国癌症杂志, 2022, 32(6): 478-486.
https://doi.org/10.19401/j.cnki.1007-3639.2022.06.002
|
[55]
|
Chauvin, J.-M. and Zarour, H.M. (2020) TIGIT in Cancer Immunotherapy. Journal for ImmunoTherapy of Cancer, 8, e000957. https://doi.org/10.1136/jitc-2020-000957
|
[56]
|
Brazel, D., Ou, S.I. and Nagasaka, M. (2023) Tiragolumab (An-ti-TIGIT) in SCLC: Skyscraper-02, a Towering Inferno. Lung Cancer: Targets and Therapy, 14, 1-9. https://doi.org/10.2147/LCTT.S379389
|
[57]
|
Marin-Acevedo, J.A., Kimbrough, E.O. and Lou, Y. (2021) Next Generation of Immune Checkpoint Inhibitors and beyond. Journal of Hematology & Oncology, 14, Article No. 45. https://doi.org/10.1186/s13045-021-01056-8
|
[58]
|
Qu, J., Mei, Q., Chen, L. and Zhou, J. (2020) Chimeric Antigen Receptor (CAR)-T-Cell Therapy in Non-Small-Cell Lung Cancer (NSCLC): Current Status and Future Perspectives. Cancer Immunology, Immunotherapy, 70, 619-631.
https://doi.org/10.1007/s00262-020-02735-0
|
[59]
|
Yilmaz, A., Cui, H., Caligiuri, M.A. and Yu, J. (2020) Chimeric Antigen Receptor-Engineered Natural Killer Cells for Cancer Immunotherapy. Journal of Hematology & Oncology, 13, Article No. 168.
https://doi.org/10.1186/s13045-020-00998-9
|
[60]
|
Hemminki, O., Dos Santos, J.M. and Hemminki, A. (2020) Oncolytic Viruses for Cancer Immunotherapy. Journal of Hematology & Oncology, 13, Article No. 84. https://doi.org/10.1186/s13045-020-00922-1
|
[61]
|
Schlom, J., Hodge, J.W., Palena, C., et al. (2014) Therapeutic Cancer Vaccines. In: Tew, K.D. and Fisher, P.B., Eds., Advances in Cancer Research, Vol. 121, Elsevier, Amsterdam, 67-124.
https://doi.org/10.1016/B978-0-12-800249-0.00002-0
|
[62]
|
Saxena, M., Van Der Burg, S.H., Melief, C.J.M. and Bhardwaj, N. (2021) Therapeutic Cancer Vaccines. Nature Reviews Cancer, 21, 360-378. https://doi.org/10.1038/s41568-021-00346-0
|
[63]
|
Saavedra, D., Neninger, E., Rodriguez, C., et al. (2018) CIMA-vax-EGF: Toward Long-Term Survival of Advanced NSCLC. Seminars in Oncology, 45, 34-40. https://doi.org/10.1053/j.seminoncol.2018.04.009
|